nuclear fast red counterstain (Vector Laboratories)
Structured Review

Nuclear Fast Red Counterstain, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1127 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nuclear fast red counterstain/product/Vector Laboratories
Average 96 stars, based on 1127 article reviews
Images
1) Product Images from "Early Binding of Anti-Amyloid Antibodies to CAA Drives Complement Activation, Inflammation and ARIA in Mice"
Article Title: Early Binding of Anti-Amyloid Antibodies to CAA Drives Complement Activation, Inflammation and ARIA in Mice
Journal: bioRxiv
doi: 10.64898/2026.03.04.709591
Figure Legend Snippet: a, Schematic of acute single-dose immunization in 19-month-old APP NL-G-F KI mice (n=3-4/group) with biotinylated 3D6 or IgG2a mAb (25 mg/kg, i.p.), followed by euthanasia at 24 h. b, Brain sections stained with Amylo-Glo (AG) for amyloid, Collagen-IV for blood vessels’ basement membrane, Streptavidin 555 for biotinylated 3D6 or IgG2a, and endothelial marker CD31 in IgG2a and 3D6-biotinylated mAb-injected mice; images taken from the leptomeningeal penetrating vessels along the cortical pial surface. Arrowheads point towards CAA-bound Streptavidin 555, indicative of biotinylated mAb binding; asterisks indicate plaques. c–d , Brain sections labeled with AG and Streptavidin-AF555 showing biotinylated mAb distribution in c, leptomeningeal vessels, and d, large parenchymal arterioles. Arrowheads indicate CAA-associated mAb binding and C1q deposition observed in 3D6-treated mice. e, Schematic of acute immunization in 25-month-old APP NL-G-F KI mice (n= 7-9/group) treated with anti-Aβ 3D6 IgG2a mAb or IgG2a isotype control. f, Brain sections stained for aggregated Aβ, anti-mouse IgG2a (to detect 3D6 and IgG2a), and C1q in IgG2a control- and 3D6-treated mice. Arrows indicate cerebellar meningeal vessel-associated labeling; asterisks mark parenchymal plaque labeling. Adjacent sections were stained with Prussian blue (counterstained with nuclear fast red) for microhemorrhages and H&E for RBC extravasation. g, Triple labeling with AG, anti-mouse IgG2a, and collagen-IV to distinguish plaque (AG⁺AntiMsIgG2a⁺ColIV⁻) and vascular (AG⁺AntiMsIgG2a⁺ColIV⁺) mAb binding in 3D6-treated brain sections. h, Quantification of % cerebellar plaque vs CAA labeling of mAb in a subset of 3D6 treated mice (n=5), *p < 0.05, paired t-test. Scale bar: b=50 µm; c,d,f =100 µm; g = 250 µm.
Techniques Used: Staining, Membrane, Marker, Injection, Binding Assay, Labeling, Control
Figure Legend Snippet: a, Schematic of 7-week treatment in 16.5-month-old APP/PS1dE9;hAPOE4 mice (n = 7-8/group) with 3D6 or IgG2a control mAb. b, Prussian blue-labeled hemosiderin deposits in cortex indicating microhemorrhage (asterisks). Scale bar: 50 µm. c, Quantification of Prussian blue–positive area (%) in the whole sagittal brain section; Mann-Whitney test, p < 0.0005. d, Amylo-Glo (AG)–positive fibrillar amyloid area (%) in cortex; unpaired t-test, p < 0.0005. e, Prussian blue staining with eosin counterstain in cortex showing hemosiderin deposits (asterisks) and red-orange cytoplasm of extravasated RBCs (arrows). Scale bar: 100 µm. f, Immunostaining with anti-mouse IgG2a fluorescently-tagged secondary antibody, C1q and AG in brain sections from 3D6- and IgG2a-treated mice. Scale bar: 50 µm. Representative immunofluorescence staining in the g, cortex and h, cerebellum showing C1q and activated C3 fragments C3b/iC3b/C3c deposition near AG-positive plaques (asterisks) and vascular amyloid (arrow), Scale bar in g & h : 250 µm. Quantification of % immunoreactivity (IR) for i, C1q; j, C1q + CD31 + AG + colocalized area; k, activated C3 fragments C3b/iC3b/C3c; and l, activated C3 fragments + CD31 + AG + colocalization in cerebellum. m, Levels of complement C3 in the plasma following 7-weeks of passive immunization. Unpaired t-test in j, k and Mann-Whitney test for i, l . *p<0.05 and **p<0.005, ***p<0.0005. Data are expressed as mean ± SEM.
Techniques Used: Control, Labeling, MANN-WHITNEY, Staining, Immunostaining, Immunofluorescence, Clinical Proteomics
